Fusion Antibodies (LON:FAB) Trading Down 20.3% – What’s Next?

Shares of Fusion Antibodies plc (LON:FAB) dropped 20.3% on Monday . The stock traded as low as GBX 9 and last traded at GBX 9.05. 2,113,557 shares traded hands during mid-day trading, an increase of 407% from the average daily volume of 416,821 shares. The stock had previously closed at GBX 11.35.

Fusion Antibodies Price Performance

The stock has a market cap of £11.33 million, a P/E ratio of -6.03 and a beta of 1.24. The business has a 50 day simple moving average of GBX 10.89 and a 200-day simple moving average of GBX 12.20. The company has a debt-to-equity ratio of 92.42, a quick ratio of 2.36 and a current ratio of 1.80.

Fusion Antibodies (LON:FAB) last released its earnings results on Monday, September 14th. The company reported GBX (1.20) EPS for the quarter. Fusion Antibodies had a negative return on equity of 210.32% and a negative net margin of 91.92%. On average, sell-side analysts forecast that Fusion Antibodies plc will post -129.9999875 EPS for the current year.

About Fusion Antibodies

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.